Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06366386
Other study ID # 5K43TW011963-03
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 15, 2024
Est. completion date May 30, 2026

Study information

Verified date June 2024
Source Infectious Diseases Research Collaboration, Uganda
Contact Emmanuel Bakashaba, Masters
Phone +256702802277
Email ebakashaba@idrc-uganda.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this implementation science study is to design evidence based and stakeholder informed implementation strategies to integrate the management of hypertension (HTN) into existing community anti-retro-viral treatment (ART) delivery models of HIV care in Uganda and evaluate their effectiveness and implementation outcomes. The main questions it aims to answer are: 1. What are the perspectives of patients (hypertensive PLHIV) on integrating hypertension care in community ART delivery models of HIV care? 2. What are the perspectives of health care providers', district leaders', and policymakers' perspectives on integrating hypertension care in community ART delivery models of HIV care? 3. What implementation strategies would support integration of the management of hypertension into existing community ART delivery models in Uganda? 4. What is the effectiveness of implementation strategies to integrate the management of hypertension care in community ART delivery models of HIV care in Uganda? 5. What are the implementation outcomes of strategies to integrate hypertension care in community ART delivery models of HIV care in Uganda? 6. What is the cumulative incidence, types and severity of HTN medication-related adverse events and their predictors among PLHIV with HTN? Investigators will use qualitative research methods to explore key stakeholders' perspectives and preferences on integrating hypertension care in community ART delivery models in Uganda; design implementation strategies that integrate the management of hypertension into existing community ART delivery models; determine the effectiveness of implementation strategies that integrate the management of hypertension in community ART delivery models; evaluate implementation outcomes of strategies that integrate hypertension care in community ART delivery models; determine the cumulative incidence, types and severity of medication-related adverse events and their predictors; and assess the patients and provider costs, health related quality of life, cost-effectiveness of leveraging existing HIV differentiated service delivery models to screen and treat HTN among persons with HIV in Uganda.


Description:

Introduction: Over a billion people worldwide have hypertension (HTN), although 46% are unaware. Approximately a third of adult people living with HIV (PLHIV) have hypertension (HTN), partly due to increased longevity, HIV related inflammation and antiretroviral therapy (ART) use. The high prevalence of HTN exposes PLHIV to an increased risk of ischemic heart disease, stroke and kidney disease. Community delivery of antiretroviral therapy (ART) improves retention and viral load suppression for PLHIV. However, HTN management is not yet integrated into community ART delivery models in which over 50% of PLHIV receive care because initial integration efforts are focused at health facilities. Additionally, the proportion of hypertensive PLHIV with controlled blood pressure is still low (5%) in Uganda. Thus, integrating the management of HTN into community ART models could improve HTN control in PLHIV and reduce the cardiovascular diseases (CVD) risk. Treating HIV, HTN and other non-communicable diseases (NCDs) concurrently raises concerns for medication-related adverse events, including but not limited to: adverse signs and symptoms (cough, angioedema, peripheral edema) and laboratory abnormalities (hypo-/hyper-kalemia, hyponatremia, hyperglycemia, hyperlipidemia). Yet, little is known about the burden and profile of such adverse events among patients concurrently treated for HIV and HTN in low-income countries like Uganda. Availability of such information is likely to improve the safety and acceptability of integrated HIV-HTN care. Aims: This study aims: 1) To explore key stakeholders' perspectives and preferences on integrating hypertension care in community ART delivery models in Uganda; 2) To design implementation strategies that integrate the management of hypertension into existing community ART delivery models; 3) To determine the effectiveness of implementation strategies that integrate the management of hypertension in community ART delivery models and 4) To evaluate implementation outcomes of strategies that integrate hypertension care in community ART delivery models, 5) To determine the cumulative incidence, types and severity of medication-related adverse events and their predictors 6) To assess the patients and provider costs, health related quality of life, cost-effectiveness of leveraging existing HIV differentiated service delivery models to screen and treat HTN among persons with HIV in Uganda. Methods: Investigators will use mixed methods research to conduct a formative study to explore stakeholders' perspectives and preferences of integrating HTN care into community ART delivery models. Using the Consolidated Framework for Implementation Research (CFIR), investigators will determine factors that influence the integration of HTN management into community ART models. Investigators will then design implementation strategies to integrate HTN management into community ART models using group model building. Investigators will do this through rigorous engagement of stakeholders who participate in the implementation of HIV and HTN services. These will include healthcare providers, health leaders at district and health facilities as well as patient representatives. To develop generalizable implementation strategies, investigators will use the widely validated CFIR-Expert Recommendations to Implement Change (CFIR-ERIC) tool to classify the strategies. Investigators will then name, define and operationalize the implementation strategies according to Proctor et al. Then, investigators will implement and determine effectiveness of the implementation strategies using an interrupted time series analysis (ITSA) across four health facilities and their community ART delivery models. in addition, investigators will leverage a cohort of ageing PLHIV receiving both HIV and HTN care to conduct baseline laboratory investigations, with a repeat of these tests at intervals of one and six months post initiation of HTN medicines, to profile adverse events associated with HTN medications among these PLHIV. Finally, investigators will evaluate the implementation and process outcomes of the implementation strategies. Investigators will do this by quantifying HIV and HTN indicators and qualitatively exploring stakeholders' barriers and facilitators towards the integrated management of HTN within community ART models. Investigators will use the Reach Effectiveness Adoption Implementation and Maintenance (RE-AIM) framework of implementation science to conduct the process evaluation. Implications of the proposed research: This study will use rigorous implementation science methods to design implementation strategies and determine their effectiveness in integrating HTN management into community-based ART delivery models. The implementation strategies may lead to improved dual control of HIV and HTN in patients who receive care in the community. By profiling HTN medication-related adverse events and their predictors among an ageing HIV population, our study will provide a benchmark for such events, as well as build capacity on monitoring and managing medication-related adverse events among PLHIV with HTN and other NCDs. Our theory of change for integrating HTN management into community-based ART delivery models will inform Ugandan HIV and HTN guidelines and could be generalizable to other low income settings. Study findings will also demonstrate the utility of implementation science in the chronic care of HTN and HIV in the community.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1100
Est. completion date May 30, 2026
Est. primary completion date May 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult PLHIV receiving HIV care either through clinic or community based ART delivery at the selected health facilities. Exclusion Criteria: - This study will be implemented in the real world setting and the proposed HTN medications are already authorized for use in Uganda. Therefore, we will not exclude any patient from accessing HTN services (screening, treatment and monitoring) unless if any patients decline taking the medicines for whichever reason. However, special patient categories including pregnant mothers, diabetic patients and those with kidney or heart disease will be referred for specialized care.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Screening and treatment of hypertension among PLHIV in DSD models for HIV
In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.

Locations

Country Name City State
Uganda Infectious Diseases Research Collaborations (IDRCUganda) Kampala Central

Sponsors (1)

Lead Sponsor Collaborator
Infectious Diseases Research Collaboration, Uganda

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of PLHIV with controlled blood pressure (both systolic and diastolic blood pressure) Number of PLHIV with HTN who will achieve Blood pressure control (both systolic and diastolic blood pressure) after starting treatment. Six months after starting treatment of hypertension
Primary % of PLHIV with controlled blood pressure (both systolic and diastolic blood pressure) Proportion of PLHIV with HTN who will achieve Blood pressure control (both systolic and diastolic blood pressure) after starting Six months after starting treatment of hypertension
Secondary Mean blood pressure (both systolic and diastolic blood pressure) Mean blood pressure (both systolic and diastolic blood pressure) of the study participants 12 months after starting treatment
Secondary Number and % of hypertensive PLHIV with suppressed Viral load Number and proportion of hypertensive PLHIV with suppressed Viral load 12 months after starting treatment
Secondary Number and % of patients retained in care Number and proportion of patients retained in care and number 12 months after starting treatment
Secondary Number and % of PLHIV screened for HTN at least once in six months Number and proportion of PLHIV screened for HTN at least once in six months 12 months after starting treatment
Secondary Implementation costs Cost of implementing strategies to integrate the management of hypertension into differentiated service delivery for HIV. 12 months after starting treatment
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A